Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial - 27/05/14
, Robert Coleman, ProfMD b, Sten Nilsson, ProfMD c, Daniel Heinrich, MD d, Svein I Helle, MD e, Joe M O’Sullivan, ProfMD f, Sophie D Fosså, ProfMD g, Aleš Chodacki, MD h, Paweł Wiechno, MD i, John Logue, FRCR j, Anders Widmark, ProfMD k, Dag Clement Johannessen, MD l, Peter Hoskin, ProfMD m, Nicholas D James, ProfMD n, o, Arne Solberg, MD p, Isabel Syndikus, FRCR q, Nicholas J Vogelzang, ProfMD r, C Gillies O’Bryan-Tear, MRCP s, Minghua Shan, PhD t, Øyvind S Bruland, ProfMD u, Christopher Parker, MD vSummary |
Background |
Bone metastases frequently cause skeletal events in patients with metastatic castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets bone metastases with high-energy, short-range α-particles. We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases.
Methods |
In this phase 3, double-blind, randomised ALSYMPCA trial, we enrolled patients who had symptomatic castration-resistant prostate cancer with two or more bone metastases and no known visceral metastases, who were receiving best standard of care, and had previously either received or were unsuitable for docetaxel. Patients were stratified by previous docetaxel use, baseline total alkaline phosphatase level, and current bisphosphonate use, then randomly assigned (2:1) to receive either six intravenous injections of radium-223 (50 kBq/kg) or matching placebo; one injection was given every 4 weeks. Randomisation was done with an interactive voice response system, taking into account trial stratification factors. Participants and investigators were masked to treatment assignment. The primary endpoint was overall survival, which has been reported previously. Here we report on time to first symptomatic skeletal event, defined as the use of external beam radiation to relieve bone pain, or occurrence of a new symptomatic pathological fracture (vertebral or non-verterbal), or occurence of spinal cord compression, or tumour-related orthopeadic surgical intervention. All events were required to be clinically apparent and were not assessed by periodic radiological review. Statistical analyses of symptomatic skeletal events were based on the intention-to-treat population. The study has been completed and is registered with ClinicalTrials.gov, number NCT00699751.
Findings |
Between June 12, 2008, and Feb 1, 2011, 921 patients were enrolled, of whom 614 (67%) were randomly assigned to receive radium-223 and 307 (33%) placebo. Symptomatic skeletal events occurred in 202 (33%) of 614 patients in the radium-223 group and 116 (38%) of 307 patients in the placebo group. Time to first symptomatic skeletal event was longer with radium-223 than with placebo (median 15·6 months [95% CI 13·5–18·0] vs 9·8 months [7·3–23·7]; hazard ratio [HR]=0·66, 95% CI 0·52–0·83; p=0·00037). The risks of external beam radiation therapy for bone pain (HR 0·67, 95% CI 0·53–0·85) and spinal cord compression (HR=0·52, 95% CI 0·29–0·93) were reduced with radium-233 compared with placebo. Radium-223 treatment did not seem to significantly reduce the risk of symptomatic pathological bone fracture (HR 0·62, 95% CI 0·35–1·09), or the need for tumour-related orthopaedic surgical intervention (HR 0·72, 95% CI 0·28–1·82).
Interpretation |
Radium-223 should be considered as a treatment option for patients with castration-resistant prostate cancer and symptomatic bone metastases.
Funding |
Algeta and Bayer HealthCare Pharmaceuticals.
Le texte complet de cet article est disponible en PDF.Plan
Vol 15 - N° 7
P. 738-746 - juin 2014 Retour au numéro
Article précédent
- Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
- Umberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, Angelo Michele Carella, Ileana Baldi, Giorgio Inghirami, Michele Spina, Vincenzo Pavone, Marco Ladetto, Anna Marina Liberati, Anna Lia Molinari, Pierluigi Zinzani, Flavia Salvi, Pier Paolo Fattori, Alfonso Zaccaria, Martin Dreyling, Barbara Botto, Alessia Castellino, Angela Congiu, Marcello Gaudiano, Manuela Zanni, Giovannino Ciccone, Gianluca Gaidano, Giuseppe Rossi, on behalf of the Fondazione Italiana Linfomi
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber, Dirk M Zahm, Sherko Kümmel, Holger Eidtmann, Peter Klare, Jens Huober, Serban Costa, Hans Tesch, Claus Hanusch, Jörn Hilfrich, Fariba Khandan, Peter A Fasching, Bruno V Sinn, Knut Engels, Keyur Mehta, Valentina Nekljudova, Michael Untch
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?